Levobupivacaine
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Levobupivacaine: From Local Anesthesia to Gastroduodenitis
One-Sentence Summary
Levobupivacaine is the S(-)-enantiomer of bupivacaine, a long-acting local anesthetic used for regional anesthesia and surgical pain management. The TxGNN model predicts it may be effective for Gastroduodenitis, however there are currently no clinical trials and no publications specifically supporting this direction. The evidence base is limited entirely to model prediction, and known systemic toxicity risks make this a low-priority repurposing candidate at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Local/regional anesthesia (no Philippines registration on record) |
| Predicted New Indication | Gastroduodenitis |
| TxGNN Prediction Score | 99.09% |
| Evidence Level | L5 |
| Philippines Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacology, Levobupivacaine is the S(-)-enantiomer of bupivacaine that blocks Nav1.x voltage-gated sodium channels, producing long-acting local anesthesia with a somewhat better cardiac safety profile than the racemic parent compound.
Three mechanistic hypotheses connect Levobupivacaine to gastroduodenitis: (1) Anti-inflammatory effects — local anesthetics as a class can suppress neutrophil chemotaxis and downregulate pro-inflammatory cytokines (IL-1β, TNF-α, IL-6), which might theoretically suppress gastroduodenal mucosal inflammation; (2) Enteric sensory nerve modulation — Nav channels are expressed throughout the enteric nervous system (ENS) and GI mucosal cells, and their blockade could reduce local hyperalgesia and neurogenic inflammation; (3) Limited antibacterial activity — local anesthetics have demonstrated in vitro inhibitory effects against H. pylori in MIC studies, though no in vivo data exist.
None of these pathways has advanced to clinical research for gastroduodenitis. More critically, systemic administration of Levobupivacaine carries well-established cardiotoxicity (QRS prolongation, ventricular fibrillation) and neurotoxicity with an extremely narrow therapeutic window. Without a viable local delivery mechanism to the gastroduodenal mucosa, the safety barrier for this repurposing direction is very high.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Philippines Market Information
Levobupivacaine is not currently registered or marketed in the Philippines. No authorization records are on file (0 total licenses).
Safety Considerations
Please refer to the package insert for safety information.
Note: Safety data (key warnings, contraindications, drug interactions) were not retrievable at the time of this Evidence Pack generation. The following are known from general pharmacological literature: systemic Levobupivacaine carries significant cardiotoxic risk (QRS prolongation, ventricular fibrillation) and neurotoxic risk at supratherapeutic doses. These risks are directly relevant to any proposed systemic repurposing use.
Conclusion and Next Steps
Decision: Hold
Rationale: This repurposing candidate rests solely on a TxGNN model prediction (Evidence Level L5) with zero supporting clinical trials or publications, and the known systemic toxicity profile of Levobupivacaine creates a substantial safety barrier that current evidence cannot overcome.
To proceed, the following is needed:
- Retrieve full MOA data from DrugBank API (Data Gap DG002)
- Obtain TFDA/FDA Philippines package insert to extract formal warnings and contraindications (Data Gap DG001)
- Establish a plausible safe delivery route (e.g., intraluminal or topical GI administration) that avoids systemic absorption
- Demonstrate preclinical in vivo efficacy in a gastroduodenitis animal model before any clinical consideration
- At minimum one observational study, case series, or mechanistic translational study is required to advance beyond L5
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.